pills-384846_960_720-300x200-4567758Industry lawsuits filed against Governor Cuomo’s $100 million opioid tax, summarized in today’s Wall Street Journal, are raising fresh questions about the levy’s fairness and unintended side effects.

In one suit, a subsidiary of drug manufacturer Mallinckrodt reports that it is being billed 8.2 cents per tablet for a form of Oxycodone that sold for 4.7 cents per tablet. Yet the law forbids companies from passing the cost of the tax along to buyers, effectively forcing Mallinckrodt to take a loss.

“Basic economic reality dictates that if a generic manufacturer is guaranteed to lose money on its sale or distribution of an opioid medication in New York, it will abandon the New York opioid market completely,” the company said in its suit, according to the Journal.

The article further reports that “some companies are re-engineering their supply chain to avoid the new tax.” Among them is drug distributor AmerisourceBergen:

AmerisourceBergen told Mallinckrodt on Oct. 10 that it will no longer accept opioid shipments at its national distribution center in Columbus, Ohio, that are intended for New York, according to Mallinckrodt’s lawsuit. If others follow, Mallinckrodt said, manufacturers will bear the entire cost of the surcharge. Under the law, distributors that send drugs into New York from a central hub outside the state get hit by the surcharge, not the pill maker.

The industry also argues that the tax could jeopardize the availability of certain drugs for New Yorkers who legitimately need them, and could prompt New York-based pharmaceutical companies to move out of the state.

As proposed by the governor and approved by the Legislature this year, the tax applies to all opioid pain relievers sold into New York, with the exception of products sold to hospice providers and drug rehab facilities. The amount to be raised is fixed at $100 million per year, which is allocated to each company in proportion to its volume of sales after adjusting for the strength of various products. The first round of bills, covering sales in 2017, were sent to 75 companies last week, the Journal reported.

The Cuomo administration originally justified the tax on two grounds – that it would raise money for the treatment and prevention of drug abuse, and that it would create a “financial disincentive” for the overuse of opioids.

However, there was no commensurate increase in spending on drug treatment, meaning most of the new revenue is replacing existing funds that are now available to be spent on other programs – in effect, helping to balance the overall state budget.

Also, the law says the cost of the tax cannot be passed along to buyers – such as hospitals, clinics, pharmacies, health plans and patients – which would seem to negate any deterrent effect on overuse.

In a statement to the Journal, a spokesman for the governor offered another rationale for the tax – that it “helps hold big pharma responsible for the opioid crisis they helped fuel.”

As the article pointed out, however, the state is also suing opioid manufacturers and distributors for their role in the crisis. The industry contends the tax is “an improper end-run around resolution of that case.”

About the Author

Bill Hammond

As the Empire Center’s senior fellow for health policy, Bill Hammond tracks fast-moving developments in New York’s massive health care industry, with a focus on how decisions made in Albany and Washington affect the well-being of patients, providers, taxpayers and the state’s economy.

Read more by Bill Hammond

You may also like

A Closer Look at $4 Billion in State Capital Grants to Health Providers

The state has awarded $4.3 billion in health-care capital grants over the past decade, with a disproportionate share flowing to upstate providers, Health Department records show. Th Read More

Hochul’s Pandemic Study Is a $4.3 Million Flop

The newly released study of New York's coronavirus pandemic response falls far short of what Governor Hochul promised – and the state urgently needs – in the aftermath of its worst natural disaster in modern history. Read More

82 Questions Hochul’s Pandemic Report Should Answer

This is the month when New Yorkers are due to finally receive an official report on the state's response to the Covid-19 pandemic, one of the deadliest disasters in state history. T Read More

Lawmakers Seek To Revive a $10 Fee for Prescriptions That Was Dropped by DFS

A plan to require a $10.18 "dispensing fee" for filling drug prescriptions is back on the table in Albany – this time in the form of legislation rather than regulation. The Read More

Budget Deal Slows Medicaid Growth But Plants Seeds for Future Spending

The growth of New York's Medicaid spending is projected to slow but not stop as Governor Hochul and the Legislature effectively split their differences over health care in the newly enacted state budget. Read More

New Jersey’s Pandemic Report Shines Harsh Light on a New York Scandal

A recently published independent review of New Jersey's pandemic response holds lessons for New York on at least two levels. First, it marked the only serious attempt by any state t Read More

Albany Lawmakers Push a $4 Billion Tax on Health Insurance

Legislative leaders are proposing an additional $4 billion tax on health insurance plans in the upcoming state budget – but withholding specifics of how it would work. Read More

Hochul’s ‘Straight Talk’ on Medicaid Isn’t Straight Enough

Arguably the biggest Medicaid news in Governor Hochul's budget presentation was about the current fiscal year, not the next one: The state-run health plan is running substantially over budget. Read More